Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases DOI Creative Commons

Theodora Claudia Gheonea,

Mária Bogdán, Andreea-Daniela Meca

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Сен. 6, 2024

Inflammatory bowel diseases (IBD), which enclose Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory ailments. Their specific pathogenesis is not completely clarified, the worldwide incidence prevalence of IBD has been steadily growing, there still a definitive cure. The management become more targeted, with immune mediators identified to be involved in its pathogenesis. Vedolizumab, humanised monoclonal antibody binding specifically α4β7 integrin, gut-selective immunosuppressive biologic drug administered for both CD UC. With same indications as vedolizumab, ustekinumab fully human IgG1κ specificity shared p40 protein subunit cytokines interleukin (IL)-12 IL-23. Several selective IL-23p19 antibodies (risankizumab, mirikizumab, guselkumab) have also revealed admirable efficacy safety patients. Nutrition very important environmental factor associated onset progression IBD, Western diet considered contribute development IBD. In this narrative review, our aim present an overview main results from recent clinical studies on regarding diet, new treatments, vaccination.

Язык: Английский

Breaking the code: Using the Precision Health Model to guide research and clinical care DOI Creative Commons
Marilyn J. Hammer, Yvette P. Conley, Wendy A. Henderson

и другие.

Nursing Outlook, Год журнала: 2025, Номер 73(3), С. 102396 - 102396

Опубликована: Апрель 21, 2025

Precision health is a person-centered approach to and well-being that operationalized through evaluating omics-level profiles their associations with the exposome. A precision addresses challenge "one size does not fit all" in management of an individual's health. The purpose this white paper introduce Health Model its application research clinical care. An expert panel reviewed synthesized extant literature related health, current state omics' science, common exposome factors influence health/illness continuum. case study provides framework for Model. key domains are defined serve as platform development Application will provide inclusive, equitable,

Язык: Английский

Процитировано

0
Construction of a Feature Gene and Machine Prediction Model for Inflammatory Bowel Disease Based on Multi - Chip Joint Analysis DOI

Yan Chaosheng,

Jingjing Rao,

Dai Yuanyuan

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

Abstract Background Inflammatory bowel disease (IBD) is a chronic non - specific inflammatory disorder triggered by immune responses and genetic factors. Currently, there no cure for IBD, its etiology remains unclear. As result, early detection diagnosis of IBD pose significant challenges. Therefore, investigating biomarkers in peripheral blood utmost importance, as it can assist doctors the identification management IBD. Methods We employed multi chip joint analysis approach to thoroughly explore database. Based on methods such artificial neural networks (ANN), machine learning techniques, SHAP model, we developed diagnostic model To select features, utilized three algorithms: Least Absolute Shrinkage Selection Operator (LASSO), Support Vector Machine (SVM), Random Forest (RF) screen differentially expressed genes. Additionally, conducted an depth enriched molecular pathways these genes through Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) pathway enrichment analysis. Moreover, used interpret results process. Finally, examined relationship between cells. Results Through learning, identified four crucial namely LOC389023, DUOX2, LCN2, DEFA6. The was elucidate contribution model. These are primarily associated with system modulation microbial alterations. GO KEGG analyses indicated that demonstrated excellent performance Antimicrobial IL − 17 signaling pathways. By performing correlation differential cells, found M1 macrophages exhibited stable changes across all M2 macrophages, resting mast neutrophils, activated CD4 memory T cells showed differences among Conclusion have (LOC389023, DEFA6) related effects Our findings suggest algorithms outperform ANN This research provides theoretical foundation clinical diagnosis, targeted therapy, prognosis evaluation

Язык: Английский

Процитировано

0
Dietary inflammatory potential, genetic predisposition, and incidence of Crohn’s disease and ulcerative colitis DOI Creative Commons
Jun Gu, Miao Zhao, Jie Wei Zhu

и другие.

Nutrition & Metabolism, Год журнала: 2025, Номер 22(1)

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0
The Role of microRNAs in Inflammatory Bowel Disease DOI Open Access
Aneta Sokal, Sara Jarmakiewicz-Czaja, Kacper Helma

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4750 - 4750

Опубликована: Май 15, 2025

Deregulation of microRNAs (miRNAs) has been implicated in the development inflammatory bowel disease (IBD). Specific miRNAs are differentially expressed patients with IBD compared to healthy individuals. Regulation their expression can modulate response, composition intestinal microbiota, and barrier function. regulate immune response via multiple mechanisms, from Th1/Th17 regulation ferroptosis modulation NLRP3 (NOD-like receptor family, pyrin domain-containing 3) control NF-κB (nuclear factor kappa-light-chain-enhancer activated B cells) pathway. The use as biomarkers therapeutic targets may help monitor treatment support new, more individualized therapies that minimize common side effects.

Язык: Английский

Процитировано

0
Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases DOI Creative Commons

Theodora Claudia Gheonea,

Mária Bogdán, Andreea-Daniela Meca

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Сен. 6, 2024

Inflammatory bowel diseases (IBD), which enclose Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory ailments. Their specific pathogenesis is not completely clarified, the worldwide incidence prevalence of IBD has been steadily growing, there still a definitive cure. The management become more targeted, with immune mediators identified to be involved in its pathogenesis. Vedolizumab, humanised monoclonal antibody binding specifically α4β7 integrin, gut-selective immunosuppressive biologic drug administered for both CD UC. With same indications as vedolizumab, ustekinumab fully human IgG1κ specificity shared p40 protein subunit cytokines interleukin (IL)-12 IL-23. Several selective IL-23p19 antibodies (risankizumab, mirikizumab, guselkumab) have also revealed admirable efficacy safety patients. Nutrition very important environmental factor associated onset progression IBD, Western diet considered contribute development IBD. In this narrative review, our aim present an overview main results from recent clinical studies on regarding diet, new treatments, vaccination.

Язык: Английский

Процитировано

0